CML

Our research and trials staff are dedicated and experienced professionals, interested in pushing the boundaries of our knowledge and testing new ideas in practical environments. Use the links below to jump to categorised trials.

SPIRIT2
Type: NCRI, multi-centre phase III randomised trial
Eligibility: Newly diagnosed CML in chronic phase Age >18 years
Study details: Compares Imatinib 400 vs Dasatanib 100